Advocate for Invasive Lobular Carcinoma (ILC) Breast Cancer patients. Rationally exuberant for Immuno-Oncology.
California, USA
Joined June 2015
- Tweets168
- Following126
- Followers491
- Likes1.6K
Pinned Tweet
First ever International #Lobular #breast #cancer symposium. Pittsburgh, PA, USA. Sept 2016. xitter.cf/mjsikora/status/672128…
Great news!
Save the date May 14-16, 2020, for 2nd International ILC Symposium In #Pittsburgh @LobularBCA #lobmob #Lobular #bcsm @LPseattle @hiplinemedia @Otto_DFCI @PWBDerksen @c_sotiriou @UPMCHillmanCC @mjsikora @BCRFcure @SusanGKomen
#Lobular related abstracts at #AACR19
TMB, PD-L1 status & Checkpoint Inhibitors
abstractsonline.com/pp8/?sf1…
[18F]FDG PET/CT imaging
abstractsonline.com/pp8/?sf1…
NCI-MATCH EAY131 arm B: Phase II study of afatinib in patients with HER2 (ERBB2) activating mutations
abstractsonline.com/pp8/?sf1…
Great news for the #Lobular breast cancer community.
New Lobular Breast Cancer Registry Will Shed Light on Rare Disease consultqd.clevelandclinic.or… via @CleClinicMD
Susan Potter (breast cancer survivor) gave her body to science. Her cadaver became immortal. nationalgeographic.com/magaz… via @NatGeo
Small historical studies reveal ~50% of Lobular breast cancers over-express ROR1 (not to be confused with ROS1). If validated, could Anti-ROR1 CAR-T immunotherapy be a future option for mILC?
CAR T-Cell Therapy Shows Early Potential in TNBC shar.es/aaYRVD via @onclive
Lobular Research retweeted
#SABCS18 Desmedt on lobular cancer progression and endocrine resistance. Uses 73 matched primary and mets (great). Increased ESR1, IGF1R, HER2 mutations. Increased AKT1. Each of these has potential to alter therapy.
Lobular Research retweeted
Impassion 130: PD-L1 expression on TILs best predictor of benefit from atezo (immune checkpoint inhibitor). Even expression at 1% level showed benefit. All metastatic TNBC should be tested for PD-L1 on TILs. #SABCS18 Atezo likely to be FDA approved in this setting in near future – at San Antonio, TX
Lobular Research retweeted
Bringing together Clinical and Biomedical Scientists @cancercenterumc for the 1st European #ILC consortium meeting. Inspiring interactive sessions building towards an improved diagnosis and tailored treatment of #lobular #breastcancer! #ILBC #DerksenLab #UMCUtrecht
More pre-clinical evidence that suggests synergy between CDK4/6 inhibitors and Checkpoint Blockade to overcome resistance. Perhaps endocrine-sensitive tumors like #Lobular could benefit. Clinical trials needed.
In @CellCellPress: A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade fal.cn/S5Fx
Wow! Didn’t realize Dr. Leisha Emens was at UPMC. As a thought leader in immunotherapy for breast cancer, this is a big win for Pitt and perhaps a potential windfall for the #Lobular community.
Anti-PD-L1 activity in TNBC. Durable clinical response when given in earlier lines of therapy and when PD-L1 high in immune cells. Proud to have lead author Leisha Emens now as a colleague here in Pittsburgh @UPMCnews @PittTweet @Magee_Womens #bcsm ja.ma/2NhB3BS
Intra-lesion genetic heterogeneity in LCIS should be considered in studies aiming to develop biomarkers of progression from LCIS to invasive disease.
Great work published yesterday in Clinical Cancer Research by my colleagues Jorge Reis-Filho, Tari King and others on the clonal relatedness of lobular carcinoma in situ and subsequent invasive breast cancers.
clincancerres.aacrjournals.o…
#breastcancer #LCIS @AACR @sloan_kettering
Tumor-suppressor genes are often inactivated through changes in mRNA processing that enable expression of truncated proteins. This mechanism of inactivation does not require DNA mutations in the affected genes. mskcc.org/blog/scientists-fi…
Lobular Research retweeted
Today, hospital said it was reducing $108,000 out-of-pocket bill to $782?! @khnews' @chadterhune @npr. Having a journalist's expose settle a bill is not triumph, it's a symptom of a very broken system, as in my book #AnAmericanSickness khn.org/news/a-jolt-to-the-j… – at Washington, DC
Visitor of the Week: Koen Schipper currentexchange.cshl.edu/blo…
One of the scientists unraveling #Lobular BC. Thankful for Jos Jonkers Lab in the Netherlands.
Still, the ILC research community is small and there’s plenty of room for more discoveries & researchers.
Lobular Research retweeted
Wonderful news about Steve Rosenberg, Jim Allison & Carl June for 2018 @AlbanyMed Prize in Medicine & Biomedical Research. Their development of immunotherapy to treat cancer is being recognized for "altering the course of medical research." Congratulations to 3 Great Scientists!
